Please enable JavaScript
Powered by Benchmark Matribhumi Samachar English - Page 953 of 2738 -
Tuesday, January 20 2026 | 01:23:16 AM

St. Augustine Closes Private Placement

Singapore, Singapore–(Newsfile Corp. – July 25, 2025) – St. Augustine Gold and Copper Limited (TSX: SAU) (“St. Augustine” or the “Company“) is pleased to announce that its previously announced (June 9, 2025) non-brokered private placement financing of 341,038,196 common shares of the Company (the “Shares“) has closed at a price …

Read More »

Early Warning Press Release in Accordance with National Instrument 62-103

Vancouver, British Columbia–(Newsfile Corp. – July 25, 2025) – Catcher Investments Ltd. (the “Acquiror“) acquired 3,000 unsecured convertible debentures (each a “Convertible Debenture“) of Optimi Health Corp. (the “Issuer“) at a price of CAD$1,000 per Convertible Debenture for a total investment of CAD$3,000,000 pursuant to a non-brokered private placement. The …

Read More »

Early Warning Press Release in Accordance with National Instrument 62-103

Vancouver, British Columbia–(Newsfile Corp. – July 25, 2025) – Cathay Visions Enterprises Ltd. (the “Acquiror“) acquired 450 unsecured convertible debentures (each a “Convertible Debenture“) of Optimi Health Corp. (the “Issuer“) at a price of CAD$1,000 per Convertible Debenture for a total investment of CAD$450,000 pursuant to a non-brokered private placement. …

Read More »

Scryb Announces Proposed Share Consolidation

Toronto, Ontario–(Newsfile Corp. – July 25, 2025) – Scryb Inc. (CSE: SCYB) (“Scryb” or the “Company”) announces a proposed consolidation of the common shares of the Company (the “Common Shares“) on the basis of ten (10) pre-consolidation Common Shares for every one (1) post-consolidation Common Share (the “Consolidation“). The Company currently …

Read More »

Phio Pharmaceuticals Announces Agreement with U.S. Manufacturing Source for Drug Substance

Agreement covers contract development and manufacturing of lead compound PH-762 King of Prussia, Pennsylvania–(Newsfile Corp. – July 25, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today it has entered into …

Read More »

Scorpio Announces Equity Issuances

Vancouver, British Columbia–(Newsfile Corp. – July 25, 2025) – Scorpio Gold Corporation (TSXV: SGN) (OTCQB: SRCRF) (FSE: RY9) (“Scorpio Gold“, or the “Company“) announces it has granted the following (the “Equity Award Grants“) to consultants and employees of the Company: (i) 8,600,000 stock options (“Options“), exercisable at $0.25 for five …

Read More »